The rationale for re-administration of genetically engineered biological drugs in patients with COVID-19


I.S. Burashnikova

Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia,
Currently, there are no evidence-based data to recommend the use of repeated doses of interleukin-6 (IL-6) blockers for the treatment of patients with COVID-19. To date, the data on the effectiveness of IL-6 blockers are contradictory. The use of drugs of this group can increase the risk of suppression of the immune system with a decrease in resistance to infectious agents.

Similar Articles

Бионика Медиа